Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03263650 · ClinicalTrials.gov registry record · Phase 2

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

A Phase 2 study of Prostate Carcinoma and Prostate Cancer Aggressiveness, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
96
Enrollment target
1
Study location

NCT03263650 is a Phase 2 study of Prostate Carcinoma and Prostate Cancer Aggressiveness that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 96 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03263650, a Phase 2 study of Prostate Carcinoma and Prostate Cancer Aggressiveness, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if olaparib, when given after treatment with cabazitaxel, carboplatin, and prednisone, can help to control aggressive variant prostate cancer (AVPC). The safety of these drugs will also be studied. This is an investigational study. Cabazitaxel and carboplatin are FDA approved and commercially available for the treatment of certain types of prostate cancer. Prednisone is FDA-approved and commercially available as a corticosteroid. Olaparib is FDA approved and commercially available for the treatment of certain types of ovarian cancer. The combination of cabazitaxel and carboplatin followed by olaparib in this study is investigational. The study doctor can describe how the study drugs are designed to work. Up to 96 participants will be enrolled on this study. All will take part at MD Anderson.

Conditions Studied

Prostate Carcinoma Prostate Cancer Aggressiveness

Interventions

  • DRUG Carboplatin
  • DRUG Olaparib
  • DRUG Cabazitaxel
  • DRUG Prednisone 5Mg

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2017-10-03
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03263650

The ClinicalTrials.gov registry entry for NCT03263650 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT03263650 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03263650 about?

NCT03263650 is a clinical study titled "Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC". The goal of this clinical research study is to learn if olaparib, when given after treatment with cabazitaxel, carboplatin, and prednisone, can help to control aggressive variant prostate cancer (AVPC). The safety of these drugs will also be studied. This is an investigational study. Cabazitaxel an...

What is the current status of trial NCT03263650?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2017-10-03. Estimated completion is 2026-06-30.

What conditions does trial NCT03263650 study?

This clinical trial studies the following conditions: Prostate Carcinoma, Prostate Cancer Aggressiveness.

What interventions are being tested in trial NCT03263650?

The interventions under investigation include: Carboplatin (DRUG), Olaparib (DRUG), Cabazitaxel (DRUG), Prednisone 5Mg (DRUG).

Who is sponsoring clinical trial NCT03263650?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03263650 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Carcinoma

All registered trials for this condition

Prostate Cancer Aggressiveness

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.